Showing results (281-290 of 3,787) with videos related to

Sort By:
Pageof 379
Oncoimmunology|June 23, 2017
Innate γδT17 cells play a protective role in DSS-induced colitis via recruitment of Gr-1+CD11b+ myeloid suppressor cellsXuan Sun, Yihua Cai, Chris Fleming, et al.
Oncoimmunology|June 23, 2017
Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effectsGrégory Ehx, Gilles Fransolet, Laurence de Leval, et al.
Oncoimmunology|April 26, 2017
Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cellsCaroline Theresa Seebauer, Stefan Brunner, Gabriel Glockzin, et al.
Oncoimmunology|April 11, 2018
Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cellsFriedrich Foerster, Sebastian Boegel, Rosario Heck, et al.
Oncoimmunology|April 11, 2018
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytesKonrad Gabrusiewicz, Xu Li, Jun Wei, et al.
Oncoimmunology|April 11, 2018
Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinomaKyu Seo Kim, Rishi R Sekar, Dattatraya Patil, et al.
Oncoimmunology|April 11, 2018
A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive propertiesMeng Shen, Jian Wang, Wenwen Yu, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
Oncoimmunology|July 7, 2017
Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathwayYanling Sun, Zu'an Zheng, Huafeng Zhang, et al.
Oncoimmunology|July 7, 2017
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunityZuqiang Liu, Xingxing Hao, Yi Zhang, et al.
Pageof 379